[go: up one dir, main page]

TN2009000345A1 - Aryl carboxylic acid cyclohexyl amide derivatives - Google Patents

Aryl carboxylic acid cyclohexyl amide derivatives

Info

Publication number
TN2009000345A1
TN2009000345A1 TNP2009000345A TN2009000345A TN2009000345A1 TN 2009000345 A1 TN2009000345 A1 TN 2009000345A1 TN P2009000345 A TNP2009000345 A TN P2009000345A TN 2009000345 A TN2009000345 A TN 2009000345A TN 2009000345 A1 TN2009000345 A1 TN 2009000345A1
Authority
TN
Tunisia
Prior art keywords
carboxylic acid
amide derivatives
acid cyclohexyl
aryl carboxylic
cyclohexyl amide
Prior art date
Application number
TNP2009000345A
Other languages
English (en)
Inventor
Rene Hersperger
Philipp Janser
Wolfgang Miltz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2009000345A1 publication Critical patent/TN2009000345A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
TNP2009000345A 2007-02-19 2009-08-17 Aryl carboxylic acid cyclohexyl amide derivatives TN2009000345A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07102622 2007-02-19
PCT/EP2008/051951 WO2008101905A1 (fr) 2007-02-19 2008-02-18 Dérivés cyclohexyl amide d'acide carboxylique aryle

Publications (1)

Publication Number Publication Date
TN2009000345A1 true TN2009000345A1 (en) 2010-12-31

Family

ID=38058317

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000345A TN2009000345A1 (en) 2007-02-19 2009-08-17 Aryl carboxylic acid cyclohexyl amide derivatives

Country Status (35)

Country Link
US (1) US8354431B2 (fr)
EP (1) EP2125782B1 (fr)
JP (1) JP5180234B2 (fr)
KR (1) KR101070984B1 (fr)
CN (1) CN101605781B (fr)
AR (1) AR065369A1 (fr)
AT (1) ATE518854T1 (fr)
AU (1) AU2008219317B2 (fr)
BR (1) BRPI0807625A2 (fr)
CA (1) CA2677565C (fr)
CL (1) CL2008000497A1 (fr)
CR (1) CR10957A (fr)
CY (1) CY1111984T1 (fr)
DK (1) DK2125782T3 (fr)
EA (1) EA017000B1 (fr)
EC (1) ECSP099584A (fr)
ES (1) ES2371126T3 (fr)
GT (1) GT200900226A (fr)
HN (1) HN2009001607A (fr)
HR (1) HRP20110793T1 (fr)
IL (1) IL200191A (fr)
MA (1) MA31206B1 (fr)
MX (1) MX2009008145A (fr)
MY (1) MY147487A (fr)
NZ (1) NZ578663A (fr)
PE (1) PE20081785A1 (fr)
PL (1) PL2125782T3 (fr)
PT (1) PT2125782E (fr)
RS (1) RS51986B (fr)
SI (1) SI2125782T1 (fr)
TN (1) TN2009000345A1 (fr)
TW (1) TW200848038A (fr)
UA (1) UA97389C2 (fr)
WO (1) WO2008101905A1 (fr)
ZA (1) ZA200905160B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
AU2021385572A1 (en) 2020-11-25 2023-06-22 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids, and related methods of use
WO2023230587A2 (fr) 2022-05-25 2023-11-30 Akagera Medicines, Inc. Nanoparticules lipidiques pour l'administration d'acides nucléiques et leurs procédés d'utilisation

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69535327T2 (de) 1994-01-13 2007-06-06 The Regents Of The University Of California, Oakland Monocyten protein rezeptoren aus säugern, mit chemoattraktion auslösender wirkung
EP1199360A3 (fr) 1996-03-01 2002-05-02 Euroscreen S.A. Récepteurs actifs et inactifs de CC-chimiokine et molécules d'acide nucléique encodant celles-ci
WO1997045543A2 (fr) * 1996-05-28 1997-12-04 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health Recepteur 5 de cc chemokine, anticorps diriges contre ce dernier et animaux transgeniques
US6388055B1 (en) 1996-10-03 2002-05-14 Smithkline Beecham Corporation Mouse CC-CKR5 receptor polypeptide
AR008331A1 (es) 1997-01-23 1999-12-29 Smithkline Beecham Corp Compuestos antagonistas de un receptor de il-8, uso de los mismos para la fabricacion de medicamentos, procedimiento para su obtencion, composicionesfarmaceuticas que los contienen
EP1039899A2 (fr) * 1997-12-19 2000-10-04 Takeda Chemical Industries, Ltd. Composition pharmaceutique antagoniste de ccr5 et contenant un derive d'anilide
US6312689B1 (en) * 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
CA2353635A1 (fr) * 1998-12-21 2000-06-29 Takeda Chemical Industries, Ltd. Derive de anilide, sa production et son utilisation
WO2001051077A1 (fr) 2000-01-14 2001-07-19 The Government Of The United States Of Americarep Resented By The Secretary, Department Of Health And Human Services Methodes de regulation de la production de il-12 par l'administration d'agonistes et d'antagonistes de ccr5
PL366062A1 (en) 2000-09-08 2005-01-24 Micromet Ag Antibody and/or chemokine constructs and their use in immunological disorders
RU2004109818A (ru) 2001-10-03 2005-05-10 Юсиби, С.А. (Be) Производные пирролидинона
US20060251651A1 (en) * 2002-12-13 2006-11-09 Ono Pharmaceutical Co., Ltd. Antagonist and agonist which bind to a strong binding site of chemokine receptor
US20070270429A1 (en) * 2003-05-06 2007-11-22 Shiro Shibayama Function Inhibitor of Effector Cell
CA2548502A1 (fr) * 2003-12-11 2005-06-30 Yale University Methodes et compositions relatives a un antagoniste du ccr5, et inflammation induite par ifn-.gamma. et il-13
EP1696919B1 (fr) * 2003-12-18 2013-10-02 Incyte Corporation Derives 3-cycloalkylaminopyrrolidine utilises en tant que modulateurs des recepteurs de chimiokine
GB0403038D0 (en) * 2004-02-11 2004-03-17 Novartis Ag Organic compounds
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
AP2314A (en) 2004-05-11 2011-10-31 Incyte Corp 3- 4-heteroarylcyclohexylamino cyclopentanecarboxamides as modulators of chemokine receptors.
GB0412468D0 (en) 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
US20070149557A1 (en) 2005-11-21 2007-06-28 Amgen Inc. CXCR3 antagonists
GB0525957D0 (en) 2005-12-21 2006-02-01 Astrazeneca Ab Methods
BRPI0712843A2 (pt) 2006-06-12 2012-07-31 Pfizer Prod Inc antagonista de ccr5 e seus usos
US20080076120A1 (en) * 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
JP2010505878A (ja) 2006-10-05 2010-02-25 セントコア・オーソ・バイオテツク・インコーポレーテツド 線維症の処置のためのｃｃｒ２アンタゴニスト
WO2008045564A2 (fr) 2006-10-12 2008-04-17 Epix Delaware, Inc. Composés de carboxamide et leur utilisation
JP2010510224A (ja) 2006-11-17 2010-04-02 アボット・ラボラトリーズ ケモカイン受容体拮抗薬としてのアミノピロリジン類
CA2676352A1 (fr) 2007-02-15 2008-08-21 Pfizer Limited Compositions pharmaceutiques et procedes pour la fabrication d'antagonistes ccr5
WO2008134076A1 (fr) 2007-04-30 2008-11-06 Progenics Pharmaceuticals, Inc. Procédés de réduction de la charge virale chez des patients infectés par le vih-1

Also Published As

Publication number Publication date
KR101070984B1 (ko) 2011-10-06
UA97389C2 (en) 2012-02-10
PL2125782T3 (pl) 2011-12-30
EP2125782A1 (fr) 2009-12-02
ZA200905160B (en) 2010-05-26
NZ578663A (en) 2011-01-28
PT2125782E (pt) 2011-11-17
EP2125782B1 (fr) 2011-08-03
BRPI0807625A2 (pt) 2014-05-27
CN101605781A (zh) 2009-12-16
CL2008000497A1 (es) 2008-08-29
US20100016361A1 (en) 2010-01-21
HN2009001607A (es) 2011-11-23
KR20090103943A (ko) 2009-10-01
GT200900226A (es) 2010-07-02
CA2677565A1 (fr) 2008-08-28
US8354431B2 (en) 2013-01-15
CR10957A (es) 2009-09-01
ATE518854T1 (de) 2011-08-15
MX2009008145A (es) 2009-08-12
AR065369A1 (es) 2009-06-03
HK1138836A1 (en) 2010-09-03
ECSP099584A (es) 2009-09-29
MA31206B1 (fr) 2010-02-01
HRP20110793T1 (hr) 2011-11-30
TW200848038A (en) 2008-12-16
CY1111984T1 (el) 2015-11-04
JP2010519187A (ja) 2010-06-03
PE20081785A1 (es) 2009-01-12
ES2371126T3 (es) 2011-12-27
MY147487A (en) 2012-12-14
EA017000B1 (ru) 2012-09-28
EA200901085A1 (ru) 2010-02-26
CN101605781B (zh) 2014-08-13
SI2125782T1 (sl) 2011-12-30
AU2008219317B2 (en) 2011-09-08
WO2008101905A1 (fr) 2008-08-28
CA2677565C (fr) 2014-11-18
IL200191A (en) 2013-12-31
AU2008219317A1 (en) 2008-08-28
JP5180234B2 (ja) 2013-04-10
IL200191A0 (en) 2010-04-15
RS51986B (sr) 2012-02-29
DK2125782T3 (da) 2011-11-21

Similar Documents

Publication Publication Date Title
TW200740758A (en) Benzoquinazoline derivatives
IL205354A0 (en) Spiroindolinone derivatives
MX2009003081A (es) Derivados de pirrola utiles para el tratamiento de enfermedades mediadas por citoquinas.
TW200801000A (en) Spiroindolinone derivatives
IL193620A0 (en) Spiroindolinone derivatives
BRPI0716598A2 (pt) Derivados de (hetero) arilsulfonamida de n-biarila úteis no tratamento de doenças medidas por interações de linfócitos
IL205506A0 (en) Spiroindolinone derivatives as anticancer agents
TW200612958A (en) Substituted imidazole derivatives
WO2006049835A3 (fr) Derives d'indole et de benzimidazole
UA102518C2 (ru) Способ синтеза ивабрадина и его аддитивных солей с фармацевтически приемлемой кислотой
MX2012003982A (es) Pirrolidinas n-substituidas.
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
EP2581372A4 (fr) Dérivé de cyanoquinoline
UA105527C2 (uk) Сполука-інгібітор матриптази для лікування раку
PT1753723E (pt) Derivados de quinolina substituída como inibidores de quinesina mitótica
TN2009000178A1 (en) Substituted pyrazole and triazole compounds as ksp inhibitors
TNSN08369A1 (en) Benzimidazole derivatives
TNSN06220A1 (en) Benzimidazole derivatives
TN2009000345A1 (en) Aryl carboxylic acid cyclohexyl amide derivatives
WO2006083841A3 (fr) Esters therapeutiques
MY145122A (en) Phenylacetic acid derivatives as cox-2 inhibitors
PH12012502478A1 (en) Isoquinoline derivative
MX2009003640A (es) Derivados de acidos vinilogos como inhibidores de quimasa.